IMV Aktie [WKN DE: A2JLZ3 / ISIN: CA44974L1031]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu IMV Inc Registered Shs

01.09.23		IMV Accepts an Offer from its Secured Lenders for the Sale of its Intellectual Property Assets (Businesswire)
08.05.23		IMV Receives NASDAQ Delisting Notice (Businesswire)
01.05.23		IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives (Businesswire)
31.03.23		IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Businesswire)
27.03.23		IMV Inc. Announces Changes to Its Board of Directors (Businesswire)
16.03.23		IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results (Businesswire)
09.03.23		IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023 (Businesswire)
13.02.23		IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial (Businesswire)
08.01.23		IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S (Businesswire)
20.12.22		IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Businesswire)
16.12.22		IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (Businesswire)
15.12.22		IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL (Businesswire)
13.12.22		IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split (Businesswire)
07.12.22		IMV Shareholders Approve Reverse Stock Split at 88% (Businesswire)
25.11.22		IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities (Businesswire)
10.11.22		IMV Inc. Announces Third Quarter 2022 Financial and Operational Results (Businesswire)
08.11.22		IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022 (Businesswire)
30.09.22		IMV Provides an Update on The VITALIZE Trial (Businesswire)
15.09.22		IMV To Slash Workforce By Around One Third (RTTNews)
15.09.22		IMV Inc. Announces Strategic Reorganization (Businesswire)
01.09.22		IMV Inc. to Present at Two Investor Conferences in September (Businesswire)
11.08.22		IMV Inc. Announces Second Quarter 2022 Financial and Operational Results (Businesswire)
05.08.22		IMV Re-Establishes Its At-the-Market Facility Under Renewed Base Shelf Prospectus (Businesswire)
04.08.22		IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022 (Businesswire)
08.07.22		IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency (Businesswire)
30.06.22		IMV Announces Annual and Special Meeting of Shareholders Voting Results (Businesswire)
22.06.22		IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility (Businesswire)
17.05.22		IMV Inc. to Present at the H.C. Wainwright Global Investment Conference (Businesswire)
13.05.22		IMV Inc. Announces First Quarter 2022 Financial and Operational Results (Businesswire)
06.05.22		IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022 (Businesswire)
28.04.22		IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting (Businesswire)
22.04.22		IMV Inc. Names Michael P. Bailey Chairman of The Board (Businesswire)
08.04.22		IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting (Businesswire)
06.04.22		IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting (Businesswire)
04.04.22		IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)
17.03.22		IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results (Businesswire)
10.03.22		IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022 (Businesswire)
09.03.22		IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022 (Businesswire)
17.02.22		IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform (Businesswire)
12.01.22		IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL (Businesswire)
05.01.22		IMV Inc. to Present at Two Upcoming Investor Events (Businesswire)
22.12.21		IMV Names Andrew Hall CEO - Quick Facts (RTTNews)
22.12.21		IMV Appoints Andrew Hall as Chief Executive Officer (Businesswire)
21.12.21		IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts (Businesswire)
20.12.21		IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility (Businesswire)
02.12.21		Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress (Businesswire)
30.11.21		IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer (Businesswire)
22.11.21		IMV Says CFO Pierre Labb Will Retire In End March - Quick Facts (RTTNews)
09.06.21		IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor (Businesswire)
13.05.21		IMV Inc. to Present at Two Upcoming Investor Conferences (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Neuer Rekord nicht mehr weit: Bitcoin, Ethereum, Litecoin & Co.: Wie sich die Kryptokurse am Mittag entwickeln

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

Nah an 100.000er Marke: Bitcoin, Dogecoin, Ethereum & Co. am Vormittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.11.2024 19:31
Kaufwert:	EUR
	Hinzufügen Speichern